University Hospital Zurich Evaluates Steriwave for Surgical Use

University Hospital Zurich (USZ) has launched a study assessing Ondine Biomedical Inc.'s Steriwave for preoperative nasal decolonization. This marks Steriwave's first application in Switzerland. The study, led by Professor Dr. Harald Essig, focuses on reducing nasal microbial load pre-surgery, a critical factor in surgical site infections (SSI).

Steriwave, an antimicrobial photodynamic therapy, uses light to activate a rapid pathogen-killing process. Unlike traditional treatments requiring multiple drug doses, it operates swiftly in a single five-minute session. Steriwave targets antibiotic-resistant strains, potentially advancing infection prevention.

Ondine Biomedical's CEO, Carolyn Cross, values USZ's research efforts, anticipating further proof of Steriwave's efficacy and safety. The Swiss study adds to its prior clinical usage in Canada and the UK, suggesting benefits in SSI prevention and antimicrobial resistance management.